Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107377 | 0.89 | TAAR1 (0.41) | TAAR1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL15841326 | 0.88 | TAAR1 (0.40) | TAAR1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL10476426 | 0.88 | TAAR1 (0.44) | TAAR1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL2116029 | 0.85 | TAAR1 (0.53) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL15060563 | 0.80 | ALDH1A1 (0.42) | TAAR1TAS1R3TAS1R1HINT1 | |
| SCHEMBL12434623 | 0.80 | ALDH1A1 (0.42) | TAAR1TAS1R3TAS1R1HINT1 | |
| SCHEMBL15048546 | 0.76 | AHCY (0.43) | — | |
| SCHEMBL2218222 | 0.76 | AHCY (0.43) | — | |
| SCHEMBL10476437 | 0.73 | TAAR1 (0.40) | TAAR1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL2215262 | 0.73 | TYMP (0.43) | TAAR1GSK3ARPS6KA3MAPK14TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479182-B1 | NOVEL PROTECTING GROUP FOR SYNTHESIZING RNA AND DERIVATIVE THEREOF | CHIRALGEN LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8470987-B2 | Protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2479182-A1 | NOVEL PROTECTING GROUP FOR SYNTHESIZING RNA AND DERIVATIVE THEREOF | Chiralgen, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | RNGTT, FBL, RNASEH1 | TAAR1 3177/4885GSK3A 4838/4885RPS6KA3 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.